Found 1 Presentation For Request "2304P"
2304P - A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
- Eun Joo Kang (Seoul, Korea, Republic of)
Abstract
Background
Tepotinib is a selective MET tyrosine-kinase inhibitor. We evaluated the efficacy and safety of tepotinib in patients with various solid cancers harboring
Methods
A phase II, multicenter, single arm study was conducted for patients with advanced or metastatic solid cancers who progressed after standard treatment, harboring either
Results
A total of 35 patients were included (
Conclusions
Tepotinib demonstrated promising antitumor activity and manageable toxicity profiles in patients with various solid cancers harboring
Clinical trial identification
NCT04647838.
Legal entity responsible for the study
The authors.
Funding
This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (HI17C2206), and partially funded by Merck KGaA, Darmstadt, Germany.
Disclosure
S.M. Lim: Financial Interests, Institutional, Local PI: AstraZeneca, Boehringer Ingelheim, Roche, GSK, Jiansu Hengrui, Amgen; Financial Interests, Institutional, Coordinating PI: BridgeBio Therapeutics; Financial Interests, Coordinating PI: Oscotec. M. Ahn: Financial Interests, Personal, Advisory Board: AstraZeneca, Takeda, MSD, Yuhan, Amgen, Alpha Pharmaceutical, Janssen, BMS, Roche, Daichi Sankyo, Merck, Voronoi. T.M. Kim: Financial Interests, Personal, Advisory Board: AstraZeneca, Janssen, Novartis, Takeda, Samsung Bioepis, Regeneron; Financial Interests, Personal, Research Grant: AstraZeneca-KHIDI; Non-Financial Interests, Principal Investigator: AstraZeneca/MedImmune, Boryung, Hanmi, Janssen, Boehringer Ingelheim, Novartis, Takeda, Sanofi, Roche/Genentech, Merck Sharp & Dohme Corp, Merck Serono, Regeneron, Genmab, Bayer, RAPT Therapeutics, Blueprint Medicines Corporation, Black Diamond Therapeutics, AbbVie, Amgen, BeyondBio Inc., Fore Biotherapeutics, Dizal Pharmaceutical, Incyte Corporation. K.H. Park: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Eli Lilly, Daichi Sankyo, Celltrion; Financial Interests, Personal, Invited Speaker: Roche, Novartis; Financial Interests, Personal, Stocks/Shares: OncoMASTER, IMBDx, SolBio; Financial Interests, Institutional, Advisory Board: Aston sciences; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Steering Committee Member: Eli Lilly; Non-Financial Interests, Institutional, Other, Non-financial research support: drug: Celltrion, Celcuity, Eli Lilly, Boryung; Non-Financial Interests, Institutional, Other, Non-financial research support: assay: IMBDx. K.H. Lee: Financial Interests, Personal, Advisory Board: BMS, MSD, Eli Lilly, Yuhan, Pfizer, AstraZeneca; Financial Interests, Funding: Merck. All other authors have declared no conflicts of interest.